



Media Release

Cordlife Earns Prestigious AABB Accreditation in Malaysia; Singapore and Hong Kong Facilities Re-accredited

- Cordlife's Malaysian subsidiary, Stemlife Berhad, attained first-time accreditation from AABB, the global leader in the development of standards for blood banking, transfusion medicine, blood management and cellular therapies.
- Cordlife Singapore and Cordlife Hong Kong yet again successfully passed AABB's numerous rigorous on-site audits.
- AABB's stamp of approval is the strongest endorsement of Cordlife Group's robust medical and technical capabilities.

SINGAPORE, 17 April 2018 – Cordlife Group Limited (“**Cordlife**”, and together with its subsidiaries, the “**Group**”) announced today that majority-owned Stemlife Berhad, Malaysia's pioneer and largest cord blood bank, received its first-ever world-class accreditation. Cordlife's Singapore and Hong Kong facilities have also been re-accredited by blood banking authority AABB.

AABB is a global leader in developing standards for blood banking, transfusion medicine, blood management and cellular therapies. Cordlife Singapore was initially accredited by AABB in 2005, becoming the first private cord blood bank in Southeast Asia to receive such esteemed recognition, while Cordlife Hong Kong earned its first in 2011. With AABB qualification, transplant physicians can be assured that cord blood units managed and stored by the Group have been handled according to the highest standards to support successful transplants anywhere in the world. To date, the Group has released cord blood units for the treatment of leukaemia, thalassemia major, cerebral palsy and other disorders to hospitals from eight countries. The Group is also one of the first private cord blood banks in Asia to release cord blood units for transplants and cellular therapy.

“There is no room for error when it comes to collecting, processing and storing cord blood, cord lining and cord tissue,” said Mr Michael Weiss, Group CEO and Executive Director of Cordlife. “Families who chose to store in unaccredited facilities should be made aware that standards could potentially fall short. Given lives could be at stake, we do not take standards lightly.”



Besides AABB, Cordlife Singapore is also accredited by FACT (Foundation for the Accreditation of Cellular Therapy), another world-class international accreditation body for cord blood banks in the world. This makes Cordlife Singapore one of just six cord blood banks in the world to be accredited by both AABB and FACT. Within the Group, facilities across Asia are also accredited by other leading standards organisations, such as ISO and the College of American Pathologists.

The endorsement from AABB reaffirms the Group's commitment to quality for safe patient and donor care; as well as to upholding the highest standards in the collection, testing, processing and storage of cord blood, cord lining and cord tissue.

"Accreditation in Malaysia and re-accreditation in Singapore and Hong Kong yet again demonstrate our medical, technical and administrative competence, and make testament to the world-class service quality and reliability that our clients have come to expect," Mr Weiss remarked.

End

Media & Investor Contact Information

WeR1 Consultants Pte Ltd

3 Phillip Street, #12-01, Royal Group Building

Singapore 048693

Tel: (65) 6737 4944

Frankie Ho – frankieho@wer1.net

Grace Yew – graceyew@wer1.net

Afina Kong – afinakong@wer1.net

About Cordlife Group Limited (Bloomberg: CLGL; Reuters: CORD.SI)

Incorporated in 2001, Cordlife Group Limited ("Cordlife", together with its subsidiaries, the "Group") is a consumer health company and one of the leading providers of cord blood as well as cord lining banking services in Asia. Cordlife has been listed on the mainboard of Singapore Exchange (SGX: P8A) since March 2012.

Cordlife owns the largest network of cord blood banks in Asia with full stem cell processing and storage facilities in six key markets namely Singapore, Hong Kong, Indonesia, India, Malaysia and the Philippines. In Singapore, Philippines and Indonesia, Cordlife operates the largest¹ private cord blood banks; and is amongst the top three market leaders in India and Malaysia. By January 2018, Cordlife became the market

¹ Source : Deloitte & Touche Financial Advisory Services Limited report, 10 April 2013



leader in Hong Kong with the acquisition of the largest private cord blood bank in the country, HealthBaby Biotech (Hong Kong) Co., Limited. Through its majority owned subsidiary, Stemlife Berhad in Malaysia, Cordlife controls indirect stake in Thailand's largest private cord blood bank, Thai Stemlife. Cordlife is also the first Singapore private cord blood bank to provide cord blood and cord lining banking services in Myanmar and Vietnam.

Beyond cord blood and cord lining banking, Cordlife offers a comprehensive suite of diagnostics services for the mother and child segment including urine-based newborn metabolic screening, non-invasive prenatal testing, paediatric vision screening and other genetic screening services.

The Group's stem cell processing and storage facilities in Singapore, Hong Kong, India and the Philippines are accredited by AABB, the organisation behind the world's gold standard for cord blood banking. Over and above, Cordlife Singapore is accredited by FACT-Netcord, another world-class accreditation body for cord blood banks globally. This makes Cordlife Singapore one of just six cord blood banks in the world to be accredited by both AABB and FACT-Netcord simultaneously. The Group's majority-owned Hong Kong Screening Centre and Cordlife India also attained accreditation from the College of American Pathologists ("CAP") for meeting the highest industry standards for laboratory services. These quality achievements underpin the Group's commitment to providing the highest service quality for clients. For more information, visit <http://cordlife.listedcompany.com>